GlobeNewswire: CytoDyn, Inc. Contains the last 10 of 10 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:02:12ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/01/28/1976051/0/en/Leronlimab-Under-Evaluation-for-Potential-Treatment-of-Coronavirus.html?f=22&fvtc=4&fvtv=57580Leronlimab Under Evaluation for Potential Treatment of Coronavirus2020-01-28T13:00:00Z<![CDATA[CytoDyn and IncellDX in discussions with potential partners about the use of leronlimab to treat 2019 Novel Coronavirus (2019-nCoV) CytoDyn and IncellDX in discussions with potential partners about the use of leronlimab to treat 2019 Novel Coronavirus (2019-nCoV)]]>https://www.globenewswire.com/news-release/2020/01/23/1974265/0/en/CytoDyn-Appoints-Maura-Fleming-as-Vice-President-General-Counsel-and-Corporate-Secretary.html?f=22&fvtc=4&fvtv=57580CytoDyn Appoints Maura Fleming as Vice President, General Counsel and Corporate Secretary2020-01-23T13:00:00Z<![CDATA[VANCOUVER, Washington, Jan. 23, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Maura Fleming as the Company’s vice president, general counsel and corporate secretary. Ms. Fleming joins CytoDyn with extensive experience in transactional, corporate and commercial law, in addition to experience in governance, securities and compliance.]]>https://www.globenewswire.com/news-release/2019/12/17/1961907/0/en/CytoDyn-Signs-Definitive-Agreements-with-Vyera-Pharmaceuticals-to-Commercialize-Leronlimab-in-the-U-S-for-the-Treatment-of-HIV.html?f=22&fvtc=4&fvtv=57580CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV2019-12-17T21:36:54Z<![CDATA[In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera will also make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock]]>https://www.globenewswire.com/news-release/2019/12/11/1959608/0/en/CytoDyn-to-Hold-Investment-Community-Conference-Call-on-December-17-2019.html?f=22&fvtc=4&fvtv=57580CytoDyn to Hold Investment Community Conference Call on December 17, 20192019-12-11T23:17:53Z<![CDATA[VANCOUVER, Washington, Dec. 11, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer, will host an investment community conference call to provide an update on the Company.]]>https://www.globenewswire.com/news-release/2019/12/03/1955477/0/en/CytoDyn-Reports-Early-Results-from-First-Patient-in-its-Phase-1b-2-CCR5-Metastatic-Triple-Negative-Breast-Cancer-Trial.html?f=22&fvtc=4&fvtv=57580CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial2019-12-03T13:00:00Z<![CDATA[First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 expression was demonstrated on cancer-associated cells after eight weeks of treatment with leronlimab]]>https://www.globenewswire.com/news-release/2019/11/21/1950625/0/en/CytoDyn-Reports-Strong-Positive-Preclinical-Data-to-Demonstrate-Potential-of-Leronlimab-in-Treating-Nonalcoholic-Fatty-Liver-Disease-NAFLD-in-Humanized-Mouse-Model.html?f=22&fvtc=4&fvtv=57580CytoDyn Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model2019-11-21T11:00:00Z<![CDATA[New preclinical data using a humanized mouse model confirms and expands on the potential use of leronlimab in treating this inflammatory syndrome, a common precursor to NASH New preclinical data using a humanized mouse model confirms and expands on the potential use of leronlimab in treating this inflammatory syndrome, a common precursor to NASH ]]>https://www.globenewswire.com/news-release/2019/11/18/1948658/0/en/CytoDyn-Engages-LifeSci-Public-Relations-as-Communications-Partner.html?f=22&fvtc=4&fvtv=57580CytoDyn Engages LifeSci Public Relations as Communications Partner2019-11-18T13:00:00Z<![CDATA[LifeSci to develop and execute comprehensive corporate communications and public relations programs LifeSci to develop and execute comprehensive corporate communications and public relations programs]]>https://www.globenewswire.com/news-release/2019/02/11/1716613/0/en/Uptick-Newswire-Hosts-CytoDyn-Inc-on-Their-Stock-Day-Podcast-to-Discuss-Revenue-Expectations-for-2020.html?f=22&fvtc=4&fvtv=57580Uptick Newswire Hosts CytoDyn Inc. on Their Stock Day Podcast to Discuss Revenue Expectations for 20202019-02-11T13:30:00Z<![CDATA[PHOENIX, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed CytoDyn Inc. (CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab (PRO 140), a novel humanized monoclonal antibody targeting the CCR5 coreceptor. President and CEO, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly.]]>https://www.globenewswire.com/news-release/2019/01/14/1691027/0/en/Uptick-Newswire-Hosts-The-President-and-CEO-of-CytoDyn-Inc-to-Discuss-The-Incredible-Potential-Breakthroughs-The-Company-is-Working-Towards-in-HIV-and-Cancer-Treatment.html?f=22&fvtc=4&fvtv=57580Uptick Newswire Hosts The President and CEO of CytoDyn Inc. to Discuss The Incredible Potential Breakthroughs The Company is Working Towards in HIV and Cancer Treatment2019-01-14T13:30:00Z<![CDATA[PHOENIX, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed CytoDyn Inc. (OTC.QB: CYDY) (the “company”), which is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. Nader Z. Pourhassan, Ph.D., President and CEO, talked with Stock Day’s Everett Jolly.]]>https://www.globenewswire.com/news-release/2018/08/27/1556822/0/en/CytoDyn-Inc-s-President-and-CEO-Nader-Pourhassan-Ph-D-Discusses-Company-Research-with-Everett-Jolly-on-Uptick-Newswire-s-Stock-Day-Podcast.html?f=22&fvtc=4&fvtv=57580CytoDyn, Inc.’s President and CEO, Nader Pourhassan, Ph.D., Discusses Company Research with Everett Jolly on Uptick Newswire’s “Stock Day” Podcast2018-08-27T11:30:00Z<![CDATA[PHOENIX, Aug. 27, 2018 (GLOBE NEWSWIRE) -- CytoDyn, Inc. (OTCQB:CYDY), (the “Company”) announced President and CEO Nader Pourhassan’s interview on Uptick Newswire’s “Stock Day” Podcast.]]>